2026 Snot Force Alliance 6th Annual Meeting (SFA)

Napa, CA US
November 13, 2026 to November 15, 2026

The 2026 Snot Force Alliance 6th Annual Meeting is focused on the field of Allergy/Immunology, ENT and Pulmonology.  It is directed to physicians, physician assistants, nurse practitioners and administrators.  The purpose is to engage the audience through oral didactic presentations followed by group discussions and case study panels that demonstrate how each specialty collaborates to improve patient outcomes. Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Snot Force Alliance (SFA).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 13.25 contact hours.

Commercial Support

Target Audience

Physicians
Physician assistants
Nurse practitioners
Administrators

Learning Objectives

At the conclusion of this activity learners should be better able to…

1. Describe the pathophysiology and clinical presentation of aspirin-exacerbated respiratory disease (AERD) and evaluate the role of biologic therapies and other treatment strategies in the management of patients with AERD.
2. Explain the unified airway model and the relationship between upper and lower airway allergic diseases and apply evidence-based strategies to manage allergic inflammation affecting both the upper and lower airway.
3. Identify emerging and non-traditional treatment approaches for common nasal and sinus conditions and evaluate the evidence supporting alternative and adjunctive therapies for sinonasal disease.
4. Recognize the relationship between gastroesophageal reflux disease (GERD) and upper airway symptoms and differentiate GERD-related symptoms from allergic and sinonasal conditions to guide appropriate management.
5. Identify clinical factors that contribute to difficult-to-treat chronic rhinosinusitis and apply advanced diagnostic and therapeutic strategies in the management of complex CRS cases.
6. Differentiate non-allergic rhinitis from allergic rhinitis and other sinonasal disorders and apply multidisciplinary management strategies to improve outcomes in patients with non-allergic rhinitis.
7. Describe the role of the microbiome in allergic disease and chronic rhinosinusitis and evaluate emerging research on microbiome-targeted therapies and their potential clinical applications.
8. Recognize clinical features that suggest underlying immune deficiency or cystic fibrosis in chronically ill patients and implement appropriate diagnostic evaluation and management strategies for patients with recurrent or persistent infections.
9. Explain the role of allergic inflammation in eustachian tube dysfunction and middle ear disease and apply treatment strategies that address allergic contributors to ear and eustachian tube disorders.
10. Identify dental causes of sinusitis and facial pain that may mimic primary sinonasal disease and develop diagnostic and management approaches for patients with odontogenic sinusitis.
11. Review emerging diagnostic tools and treatment options for obstructive sleep apnea and evaluate patient-specific factors when selecting therapies for sleep-disordered breathing.
12. Recognize how allergic rhinitis and sinonasal disease contribute to sleep-disordered breathing and incorporate treatment of allergic and inflammatory airway disease into the management of sleep apnea.
13. Identify biomarkers and clinical characteristics associated with type II inflammatory diseases and apply evidence-based guidelines to select appropriate biologic therapies for individual patients.
14. Differentiate type II from non-type II inflammatory pathways in airway disease and evaluate treatment strategies for patients with mixed or non-type II inflammatory phenotypes.
15. Recognize common presentations of sinus and allergic disease in pediatric patients and apply age-appropriate diagnostic and treatment strategies for pediatric sinonasal and allergic conditions.
16. Identify common causes of chronic cough, including upper airway cough syndrome and develop diagnostic and management strategies for patients presenting with chronic cough and post-nasal drip.
17. Recognize atypical presentations and diagnostic challenges in hereditary angioedema and anaphylaxis and apply evidence-based management strategies to complex or unusual cases of HAE and anaphylaxis.
18. Evaluate potential causes of nasal obstruction when physical examination findings are minimal or normal and develop diagnostic approaches to identify underlying conditions contributing to persistent nasal symptoms.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary

Available credit: 
  • 13.25 AMA PRA Category 1 Credit™
  • 13.25 Attendance
  • 13.25 CBRN
Course opens: 
11/13/2026
Course expires: 
12/31/2026
Event starts: 
11/13/2026 - 7:00am CST
Event ends: 
11/15/2026 - 11:15am CST
Rating: 
0

COMING SOON!

Marriott Napa Valley
3425 Solano Ave.
Napa, CA 94558
United States

COMING SOON!

Available Credit

  • 13.25 AMA PRA Category 1 Credit™
  • 13.25 Attendance
  • 13.25 CBRN
Please login or create an account to take this course.